Precision medicine clinical trials: defining new treatment strategies

Abstract

Insights

Clinical trials are evolving with new adaptive designs to personalize cancer care. These studies evaluate targeted therapies in specific patient groups, optimizing treatment delivery and identifying those most likely to benefit.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biomedical Technology

Background:

  • Cancer care is shifting towards personalized treatment plans.
  • Biomarker discovery and technological advancements are key drivers of this change.
  • Traditional clinical trial models are being adapted to meet new challenges.

Purpose of the Study:

  • To explore the role of clinical trials in personalized cancer care.
  • To discuss innovative randomized studies evaluating targeted therapies.
  • To highlight the integration of molecularly defined subsets in trial design.

Main Methods:

  • Review of medical and nursing literature.
  • Analysis of research articles.
  • Inclusion of data from clinicaltrials.gov.

Main Results:

  • Advancements in cancer biomarkers and technology are transforming cancer therapeutics.
  • Innovative adaptive trial designs are emerging.
  • Trials aim to determine not only safety and efficacy but also optimal delivery and patient benefit.

Conclusions:

  • The cancer biomarker era necessitates specialized knowledge and skills for clinical trials.
  • Understanding molecular processes and ethical considerations is crucial.
  • Competent, safe, and effective healthcare requires expertise in biomarker-driven trials and patient communication.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K